A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy
dc.contributor.author | Felip, E | |
dc.contributor.author | Brunsvig, P | |
dc.contributor.author | Vinolas, N | |
dc.contributor.author | Aix, SP | |
dc.contributor.author | Costa, EC | |
dc.contributor.author | Gomez, MD | |
dc.contributor.author | Perez, JMT | |
dc.contributor.author | Arriola, E | |
dc.contributor.author | Campelo, RG | |
dc.contributor.author | Spicer, JF | |
dc.contributor.author | Thompson, JR | |
dc.contributor.author | Granados, ALO | |
dc.contributor.author | Holt, RJ | |
dc.contributor.author | Lorens, K | |
dc.contributor.author | Lorens, JB | |
dc.contributor.author | Shoaib, M | |
dc.contributor.author | Siddiqui, A | |
dc.contributor.author | Schmidt, EV | |
dc.contributor.author | Chisamore, MJ | |
dc.contributor.author | Krebs, Matthew G | |
dc.date.accessioned | 2019-11-19T16:01:04Z | |
dc.date.available | 2019-11-19T16:01:04Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Felip E, Brunsvig P, Vinolas N, Aix S, Costa E, Gomez M, et al. A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy. J Clin Oncol. 2019;37(15). | en |
dc.identifier.doi | 10.1200/JCO.2019.37.15_suppl.9098 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622443 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.9098 | en |
dc.title | A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Hospital Universitari Vall d'Hebron, Barcelona, Spain | en |
dc.identifier.journal | Journal of Clinical Oncology | en |